BioXcel Therapeutics Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the rating peer group for BioXcel Therapeutics Inc are shown below. This Sustainability rating for BioXcel Therapeutics Inc indicates the company's reporting of the UN SDGs. Jump to the end of this webpage for potential risks for BioXcel Therapeutics Inc based on sector, location and size.
BioXcel Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.6; made up of an environmental score of 6.4, social score of 4.8 and governance score of 8.0.
6.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 446 | STADA Arzneimittel AG | 6.7 | High |
| 446 | Valeo Pharma Inc | 6.7 | High |
| 483 | BioXcel Therapeutics Inc | 6.6 | High |
| 483 | Bal Pharma Ltd | 6.6 | High |
| 483 | Adicet Bio Inc | 6.6 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does BioXcel Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes BioXcel Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes BioXcel Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes BioXcel Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes BioXcel Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes BioXcel Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes BioXcel Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes BioXcel Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid BioXcel Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes BioXcel Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas BioXcel Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes BioXcel Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes BioXcel Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs BioXcel Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes BioXcel Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes BioXcel Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes BioXcel Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for BioXcel Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.